Management of early prostate cancer

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 83-87

  Horwich, A ^a   Parker, C C ^a   Huddart, R A ^a   Dearnaley, D P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; EARLY CANCER; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES;

EID: 0036434521     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf643     Document Type: Article

References (32)

1. Albertsen P, Gleason D, Barry M. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980.
2. Padhani A, Gapinski C, MacVicar D et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55: 99-109.
3. Pound C, Partin A, Epstein J, Walsh P. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
4. Partin A, Kattan M, Subong E et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 278: 118.
5. Parker C, Norman A, Huddart R et al. Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer 2002; 86: 686-691.
6. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994; 330: 242-248.
7. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-620.
8. Walsh P. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-1807.
9. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Soc Thorac Surg 1993; 55: 986-989.
10. Madalinska JB, Essink-Bot ML, de Koning HJ et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 1619-1628.
11. Morgan WR, Bergstalh EJ, Zincke H. Long-term evaluation of radical prostatectomy for clinical stage C (T3) prostate cancer. Urology 1993; 41: 113-117.
12. Ohori M, Goad J, Wheeler T et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-1849.
13. Lu-Yao G, Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-910.
14. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385-390.
15. Zelefsky MJ, Wallner KE, Ling C et al. Comparison of the 5 year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine 125 implantation for early stage prostatic cancer. J Clin Oncol 1999; 17: 517-522.
16. Dearnaley DP, Khoo VS, Norman A et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353: 267-272.
17. Dearnaley D, Hall E, Jackson C et al. Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer. ASTRO 2002; New Orleans, 6-10 October 2002; (Abstr 7992).
18. Zagars GK, von Eschenback AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation. Cancer 1987; 60: 1489-1499.
19. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984; 10: 401-409.
20. Potosky A, Legler J, Albertsen P et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582-1592.
21. Zelefsky M, Leibel S, Gaudin P et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
22. Valicenti R, Lu J, Pilepich M et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group Trials. J Clin Oncol 2000; 18: 2740-2746.
23. Pollack A, Zaggars G, Smith L et al. Preliminary results of a randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-3911.
24. Zelefsky M, Fuks Z, Happersett L et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241-249.
25. Zeitman A, Prince E, Nakfoor B, Shipley W. Neoadjuvant androgen suppression with radiation in the management of locally advanced prostate cancer: experimental and clinical results. Urology 1997; 49 (Suppl. 3A): 74-83.
26. Forman JD, Kumar R, Haas G et al. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8-15.
27. Pilepich MV, Winter K, Roach M et al. Phase III Radiation Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 1998; 17: 308a (Abstr 1185).
28. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997; 15: 1013-1021.
29. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin (see Comments). N Engl J Med 1997; 337: 295-300.
30. Roach M, Lu J, Pilepich MV et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000; 47: 609-615.
31. Dearnaley DP, Melia J. Early prostate cancer-to treat or not to treat? Lancet 1997; 349: 892-893.
32. D'Amico AV, Whittington R, Kaplan I. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997; 37: 1053-1058.